CA
NZ
UK
AU
IND
US
…
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Axim Biotechnologies Inc. is an OTC Pink–listed small-cap biotech that describes itself as engaged in development and commercialization of pharmaceutical and health-related products, including cannabinoid-based formulations. Its long-term growth drivers could include successful product development, commercialization or licensing deals and expansion into niche therapeutic or consumer markets, which may benefit investors seeking exposure to early-stage health-care assets.
The principal investment risks are limited public disclosure, thin trading liquidity as an OTC Pink issuer, potential equity dilution from future financings and high execution and regulatory risk common to small biotech companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1.04M | -3.51M | -8.06M | -6.24M | -16.02M |
| Net income | -1.04M | -3.51M | -8.06M | -6.24M | -16.03M |
| Selling general administrative | - | 1.35M | 2.24M | 4.08M | 5.67M |
| Gross profit | -0.43M | -0.37M | 0.04M | - | - |
| Reconciled depreciation | - | 0.43M | 0.43M | 0.43M | 2.12M |
| Ebit | -1.32M | -2.88M | -6.85M | -4.65M | -8.01M |
| Ebitda | -0.89M | -2.44M | -6.43M | -3.94M | -13.42M |
| Depreciation and amortization | 0.43M | 0.43M | 0.43M | - | - |
| Operating income | -1.32M | -1.76M | -2.75M | -4.65M | -7.73M |
| Other operating expenses | 1.32M | 1.83M | 2.79M | - | - |
| Interest expense | 0.34M | 0.64M | 1.20M | 1.88M | 0.49M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | - | 0.00M | 0.00M | 0.00M |
| Net interest income | - | -0.64M | -1.20M | -1.88M | -0.74M |
| Income tax expense | - | - | 0.00M | - | - |
| Total revenue | - | 0.07M | 0.04M | 0.01M | 0.06M |
| Total operating expenses | 0.89M | 1.39M | 2.79M | 4.66M | 7.79M |
| Cost of revenue | 0.43M | 0.44M | 0.43M | - | - |
| Total other income expense net | 0.28M | -1.75M | -5.31M | 0.29M | -7.55M |
| Discontinued operations | - | - | - | - | -0.01M |
| Net income from continuing ops | - | -3.52M | -8.06M | -6.24M | -16.02M |
| Net income applicable to common shares | - | - | - | -6.24M | -16.03M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.88M | 3.45M | 4.12M | 4.21M | 5.32M |
| Intangible assets | 2.81M | 3.20M | 3.59M | 3.99M | 4.38M |
| Other current assets | - | - | - | 0.01M | 0.02M |
| Total liab | 14.24M | 13.87M | 11.78M | 9.04M | 7.66M |
| Total stockholder equity | -11.37M | -10.42M | -7.66M | -4.83M | -2.34M |
| Other current liab | 4.34M | 4.67M | 2.70M | 2.03M | 0.00M |
| Common stock | 0.03M | 0.03M | 0.02M | 0.02M | 0.01M |
| Capital stock | - | 0.03M | 0.02M | 0.02M | 0.01M |
| Retained earnings | -76.74M | -75.70M | -72.18M | -64.13M | -57.88M |
| Good will | - | - | - | - | 0.00M |
| Other assets | - | - | - | 0.01M | 0.11M |
| Cash | 0.00M | 0.00M | 0.16M | 0.05M | 0.45M |
| Total current liabilities | 6.08M | 6.76M | 5.98M | 3.39M | 2.58M |
| Current deferred revenue | - | 0.23M | 0.30M | - | - |
| Net debt | 7.78M | 6.64M | 5.74M | 5.60M | 6.19M |
| Short term debt | - | 0.08M | 0.19M | - | - |
| Short long term debt | - | - | - | - | 1.58M |
| Short long term debt total | 7.78M | 6.64M | 5.89M | - | - |
| Other stockholder equity | 65.34M | 65.25M | 64.50M | 0.09M | 4.53M |
| Property plant equipment | - | - | - | 0.11M | 0.19M |
| Total current assets | 0.00M | 0.00M | 0.16M | 0.10M | 0.64M |
| Net tangible assets | - | - | - | -8.81M | -6.72M |
| Net receivables | - | 0.00M | - | - | - |
| Long term debt | - | 7.04M | 5.66M | 5.64M | 5.06M |
| Inventory | - | 0.00M | - | - | - |
| Accounts payable | 1.74M | 1.79M | 2.78M | 1.32M | 0.85M |
| Accumulated other comprehensive income | - | - | -0.00M | - | - |
| Non currrent assets other | - | 0.01M | 0.01M | - | - |
| Non current assets total | 2.87M | 3.45M | 3.97M | 4.11M | 4.69M |
| Capital lease obligations | - | 0.14M | 0.23M | 0.02M | 0.08M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.00M | 0.00M | -0.01M | -0.05M |
| Change to liabilities | - | - | - | 0.99M | 0.28M |
| Total cashflows from investing activities | - | -0.00M | - | -0.01M | -0.05M |
| Net borrowings | - | 0.48M | 0.68M | -0.09M | 0.90M |
| Total cash from financing activities | 0.66M | 0.70M | 1.14M | 1.65M | 2.53M |
| Change to operating activities | - | - | - | 0.03M | -0.29M |
| Net income | -1.04M | -3.51M | -8.06M | -6.24M | -16.03M |
| Change in cash | 0.00M | -0.16M | 0.11M | -0.41M | -0.00M |
| Begin period cash flow | 0.00M | 0.16M | 0.05M | 0.45M | 0.46M |
| End period cash flow | 0.00M | 0.00M | 0.16M | 0.05M | 0.45M |
| Total cash from operating activities | -0.69M | -0.86M | -1.03M | -2.04M | -2.49M |
| Issuance of capital stock | - | 0.22M | 0.49M | 1.74M | 1.64M |
| Depreciation | 0.43M | 0.43M | 0.43M | 0.43M | 2.12M |
| Change to inventory | - | - | - | 0.02M | -0.02M |
| Sale purchase of stock | - | - | 0.15M | - | - |
| Other cashflows from financing activities | - | - | -0.03M | - | - |
| Change to netincome | - | - | - | 2.34M | 10.74M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.01M | 0.04M |
| Change in working capital | -0.41M | 0.78M | 1.29M | 1.04M | -0.03M |
| Stock based compensation | - | 0.00M | 0.20M | 1.11M | 1.14M |
| Other non cash items | 0.34M | 1.44M | 5.11M | 2.11M | 2.76M |
| Free cash flow | -0.69M | -0.86M | -1.03M | -2.05M | -2.54M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AXIM Axim Biotechnologies Inc |
- -% |
0.00 | - | - | 23.09 | 2.86 | 180.93 | -1.27 |
| NVO Novo Nordisk A/S |
-0.38 0.98% |
38.29 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
8.66 1.66% |
529.69 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.83 0.35% |
813.27 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
6191 Cornerstone Court, East, San Diego, CA, United States, 92121
858 923 4422
6
| Name | Title | Year Born |
|---|---|---|
| Mr. John W. Huemoeller II | Pres, CEO & Director | 1955 |
| Mr. Robert T. Malasek | CFO & Sec. | 1968 |
| Ms. Catalina Valencia J.D. | Co-Founder & CEO of Sapphire Biotech, Inc. | 1949 |
| Dr. Sergei A. Svarovsky M.B.A., Ph.D. | Chief Scientific Officer & Co-Founder of Sapphire Biotech, Inc. | NA |
| Dr. Alim Seit-Nebi Ph.D. | CTO & Co-Founder of Sapphire Biotech, Inc. | NA |
| Mr. Jeffrey A. Busby | Sr. VP of Bus. Devel. | NA |
| Dr. Joseph Tauber M.D. | Chief Medical Officer & Chairman of the Medical Advisory Board | 1957 |
| Ms. Catalina Valencia J.D. | President & Director | 1949 |
| Mr. Robert T. Malasek | CFO & Secretary | 1968 |
| Mr. Kurt Phinney | Chief Operating Officer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...